585 related articles for article (PubMed ID: 25609918)
1. Screening strategies to identify HSP70 modulators to treat Alzheimer's disease.
Repalli J; Meruelo D
Drug Des Devel Ther; 2015; 9():321-31. PubMed ID: 25609918
[TBL] [Abstract][Full Text] [Related]
2. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.
Jouanne M; Rault S; Voisin-Chiret AS
Eur J Med Chem; 2017 Oct; 139():153-167. PubMed ID: 28800454
[TBL] [Abstract][Full Text] [Related]
3. Chemical manipulation of hsp70 ATPase activity regulates tau stability.
Jinwal UK; Miyata Y; Koren J; Jones JR; Trotter JH; Chang L; O'Leary J; Morgan D; Lee DC; Shults CL; Rousaki A; Weeber EJ; Zuiderweg ER; Gestwicki JE; Dickey CA
J Neurosci; 2009 Sep; 29(39):12079-88. PubMed ID: 19793966
[TBL] [Abstract][Full Text] [Related]
4. N-Acetyl cysteine blunts proteotoxicity in a heat shock protein-dependent manner.
Jiang Y; Rumble JL; Gleixner AM; Unnithan AS; Pulugulla SH; Posimo JM; Choi HJ; Crum TS; Pant DB; Leak RK
Neuroscience; 2013; 255():19-32. PubMed ID: 24096134
[TBL] [Abstract][Full Text] [Related]
5. Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease.
García-Font N; Hayour H; Belfaitah A; Pedraz J; Moraleda I; Iriepa I; Bouraiou A; Chioua M; Marco-Contelles J; Oset-Gasque MJ
Eur J Med Chem; 2016 Aug; 118():178-92. PubMed ID: 27128182
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of Halogen-Substituted novel α-Ketoamides as potential protein aggregation modulators in Alzheimer's disease.
Das B; Tk Baidya A; Chakrabarti S; Chouhan D; Thakur B; Darreh-Shori T; Chen G; Tiwari V; Kumar R
Bioorg Chem; 2024 Jun; 147():107373. PubMed ID: 38653149
[TBL] [Abstract][Full Text] [Related]
7. Thiophene-Based Dual Modulators of Aβ and Tau Aggregation.
Ramesh M; Acharya A; Murugan NA; Ila H; Govindaraju T
Chembiochem; 2021 Dec; 22(23):3348-3357. PubMed ID: 34546619
[TBL] [Abstract][Full Text] [Related]
8. First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease.
Mariano M; Schmitt C; Miralinaghi P; Catto M; Hartmann RW; Carotti A; Engel M
ACS Chem Neurosci; 2014 Dec; 5(12):1198-202. PubMed ID: 25247807
[TBL] [Abstract][Full Text] [Related]
9. Identification of ortho catechol-containing isoflavone as a privileged scaffold that directly prevents the aggregation of both amyloid β plaques and tau-mediated neurofibrillary tangles and its in vivo evaluation.
Son SH; Do JM; Yoo JN; Lee HW; Kim NK; Yoo HS; Gee MS; Kim JH; Seong JH; Inn KS; Seo MD; Lee JK; Kim NJ
Bioorg Chem; 2021 Aug; 113():105022. PubMed ID: 34098397
[TBL] [Abstract][Full Text] [Related]
10. Heat Shock Proteins in Alzheimer's Disease: Role and Targeting.
Campanella C; Pace A; Caruso Bavisotto C; Marzullo P; Marino Gammazza A; Buscemi S; Palumbo Piccionello A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200516
[TBL] [Abstract][Full Text] [Related]
11. Hsp70 alters tau function and aggregation in an isoform specific manner.
Voss K; Combs B; Patterson KR; Binder LI; Gamblin TC
Biochemistry; 2012 Jan; 51(4):888-98. PubMed ID: 22236337
[TBL] [Abstract][Full Text] [Related]
12. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease.
Shin J
Int J Geriatr Psychiatry; 2011 May; 26(5):546-8. PubMed ID: 21446001
[No Abstract] [Full Text] [Related]
13. DYRK1A inhibition as potential treatment for Alzheimer's disease.
Stotani S; Giordanetto F; Medda F
Future Med Chem; 2016 Apr; 8(6):681-96. PubMed ID: 27073990
[TBL] [Abstract][Full Text] [Related]
14. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro.
Evans CG; Wisén S; Gestwicki JE
J Biol Chem; 2006 Nov; 281(44):33182-91. PubMed ID: 16973602
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling, virtual screening and molecular docking of ATPase inhibitors of HSP70.
Sangeetha K; Sasikala RP; Meena KS
Comput Biol Chem; 2017 Oct; 70():164-174. PubMed ID: 28910705
[TBL] [Abstract][Full Text] [Related]
16. Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer's Disease?
Doig AJ; Del Castillo-Frias MP; Berthoumieu O; Tarus B; Nasica-Labouze J; Sterpone F; Nguyen PH; Hooper NM; Faller P; Derreumaux P
ACS Chem Neurosci; 2017 Jul; 8(7):1435-1437. PubMed ID: 28586203
[TBL] [Abstract][Full Text] [Related]
17. Disassembly of Tau fibrils by the human Hsp70 disaggregation machinery generates small seeding-competent species.
Nachman E; Wentink AS; Madiona K; Bousset L; Katsinelos T; Allinson K; Kampinga H; McEwan WA; Jahn TR; Melki R; Mogk A; Bukau B; Nussbaum-Krammer C
J Biol Chem; 2020 Jul; 295(28):9676-9690. PubMed ID: 32467226
[TBL] [Abstract][Full Text] [Related]
18. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors.
Cho GW; Noh MY; Kang BY; Ku IW; Park J; Hong YH; Kim MH; Kim SH
Assay Drug Dev Technol; 2011 Oct; 9(5):503-13. PubMed ID: 21561378
[TBL] [Abstract][Full Text] [Related]
19. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
Ising C; Stanley M; Holtzman DM
Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
[TBL] [Abstract][Full Text] [Related]
20. Yeast Model of Amyloid-β and Tau Aggregation in Alzheimer's Disease.
Moosavi B; Mousavi B; Macreadie IG
J Alzheimers Dis; 2015; 47(1):9-16. PubMed ID: 26402750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
